Anticoagulation in Dialysis Patients

Anticoagulation During Dialysis Procedures

Unfractionated heparin (UFH) is the recommended standard anticoagulant for hemodialysis due to its low cost, proven efficacy, and reversibility, with standard dosing being an initial bolus of 25-50 units/kg followed by continuous infusion of 500-1500 units/hour 1, 2
UFH does not require dose adjustment for renal impairment and is not cleared by dialysis 1
Low Molecular Weight Heparins (LMWHs) can be used but require careful dosing and monitoring due to renal clearance and accumulation risk, with anti-Xa level monitoring recommended to avoid accumulation 3, 4
Critical caveat: LMWHs are contraindicated or require dose adjustment when creatinine clearance <30 mL/min, with bleeding risk up to twice as high in severe renal impairment 4
Regional citrate anticoagulation is the preferred alternative for patients with high bleeding risk or Heparin-Induced Thrombocytopenia (HIT) 2
Argatroban is ideal for acute HIT during dialysis, with standard therapeutic doses without adjustment, though close monitoring is recommended 1

Systemic Anticoagulation in Dialysis Patients

The American College of Cardiology recommends apixaban as the first choice for systemic anticoagulation in dialysis patients with atrial fibrillation, due to its favorable safety profile and lower major bleeding risk compared to warfarin 5, 6
Apixaban demonstrates a lower major bleeding risk compared to warfarin, with no difference in stroke risk, and standard 5 mg twice daily dosing is associated with the best outcomes in observational data 5, 6
Warfarin shows no apparent effect on stroke risk or mortality but increases major bleeding risk in ESRD patients, and should be reserved for highest-risk patients with prior stroke or documented cardiac thrombus 7, 6
Rivaroxaban and dabigatran are associated with increased major bleeding risk in hemodialysis patients compared to warfarin, and should be avoided in dialysis patients when other options are available 6

Special Situations

The International Society on Thrombosis and Haemostasis recommends higher heparin doses or therapeutic anticoagulation for COVID-19 and other inflammatory states that increase filter clotting despite standard anticoagulation 8
Bivalirudin requires dose reduction in patients with severe renal impairment, with 1.0 mg/kg/hour for CrCl <30 mL/min, and 0.25 mg/kg/hour for patients on hemodialysis 4
The National Comprehensive Cancer Network recommends avoiding standard LMWH doses in dialysis patients without anti-Xa monitoring, as accumulation leads to severe bleeding 3, 4

Anticoagulation in Dialysis Patients

Anticoagulation During Dialysis Procedure

The American Society of Hematology (ASH) recommends citrate regional over heparin or other non-heparin anticoagulants in patients with subacute, remote, or past heparin-induced thrombocytopenia (HIT) who are receiving renal replacement therapy 9, 10
Citrate is not appropriate for patients with acute HIT who require systemic anticoagulation instead of regional anticoagulation 9, 10

Anticoagulation in Patients with Heparin-Induced Thrombocytopenia (HIT)

For patients with acute HIT who require dialysis, the ASH suggests treatment with argatroban, danaparoid, or bivalirudina over other non-heparin anticoagulants 11
Argatroban is ideal for acute HIT during dialysis due to its lack of renal clearance and clinically insignificant dialytic removal by high-flux membranes 12
Argatroban demonstrates low rates of new thrombosis (0%-4%) and major bleeding (0%-6%) in prospective studies 12

Anticoagulant Selection Factors

Renal clearance: Argatroban is preferred due to its lack of renal clearance, making it safer in patients with renal insufficiency 9, 10
Medication availability and cost: The choice may be influenced by institutional availability and cost 9, 10, 11
Patient liver function: Should be considered when selecting the agent 9, 11
Clinician experience: Familiarity with these medications can influence the selection 9, 10, 11

Heparin Anticoagulation for Dialysis in Special Situations

Heparin-Induced Thrombocytopenia (HIT)

For acute HIT requiring dialysis, the Anaesthesia society recommends using argatroban as first-line alternative: 100 μg/kg bolus for continuous hemodialysis or 250 μg/kg for intermittent hemodialysis, followed by continuous infusion, due to its lack of renal clearance and minimal removal by high-flux dialysis membranes 13
The Anaesthesia society suggests danaparoid as an alternative with bolus dosing of 3750 units (2500 units if weight <55 kg) before the first two sessions, then 3000 units (2000 units if weight <55 kg) for subsequent sessions, although it accumulates in renal failure and is more difficult to use than argatroban 13

Anticoagulation Management in Hemodialysis

Alternative Anticoagulation Strategies

Regional citrate is the preferred alternative for patients at high bleeding risk or those who cannot receive heparin, as it provides anticoagulation limited to the extracorporeal circuit without systemic effects, according to the American Society of Hematology 14, 15
Citrate demonstrates similar efficacy to heparin with a superior safety profile, including reduced bleeding and reduced risk of heparin-induced thrombocytopenia (HIT), as recommended by the American College of Cardiology 15
Regional citrate is more cost-effective than alternative non-heparin anticoagulants, as stated by the National Kidney Foundation 15

Managing Heparin-Induced Thrombocytopenia (HIT)

For patients with acute HIT, argatroban is the first-line alternative anticoagulant, as suggested by the American Heart Association 14, 16
Alternative agents for acute HIT include danaparoid or bivalirudin, though these have more limitations, according to the American College of Chest Physicians 14, 16
For patients with subacute HIT A, subacute HIT B, or remote HIT who require anticoagulation only for the dialysis circuit, regional citrate is preferred over heparin or other non-heparin anticoagulants, as recommended by the European Renal Association 14, 15

Troubleshooting Recurrent Clotting

If pharmacologic therapy fails to prevent clotting, mechanical interventions such as catheter exchange, fibrin sheath stripping, or disruption may be necessary, as stated by the Society of Interventional Radiology 17
Avoid using low-dose prophylactic anticoagulation to prevent catheter thrombosis, as the risks may outweigh the benefits, according to the American College of Radiology 17

Anticoagulant Choice for Dialysis Patients

Intradialytic Anticoagulation

Unfractionated heparin (UFH) has a short half-life (1-2 hours after IV injection), allowing rapid reversal if bleeding occurs, making it a suitable option for patients with complete renal failure 18

Alternative Anticoagulants

Citrate demonstrates similar efficacy to heparin with superior safety profile, including reduced bleeding risk, but is not FDA-approved for CRRT in the United States and commercially available solutions are hypertonic, increasing metabolic complication risk 19
Argatroban is the first-line alternative anticoagulant for acute HIT requiring dialysis, with a critical advantage of not requiring dose adjustment in renal failure, unlike danaparoid which accumulates 20

Systemic Anticoagulation

Apixaban has only 25% renal elimination, making it less affected by renal impairment compared to other DOACs, and is the first choice for systemic anticoagulation in dialysis patients with atrial fibrillation 18
Dabigatran is 80% renally eliminated and is contraindicated when creatinine clearance <15 mL/min, and should be avoided in dialysis patients 18

Critical Considerations

Never use DOACs in patients with creatinine clearance <15 mL/min except apixaban, which can be used cautiously 18
Dialysis is not effective for removing most DOACs (except dabigatran) due to high protein binding 18

Anticoagulation in Dialysis Patients

Introduction to Anticoagulation

The National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines recommend that dialysis patients with acute coronary syndromes receive the same anticoagulation as the general population, with unfractionated heparin (UFH) being preferred over low molecular weight heparin (LMWH) due to altered drug clearances in kidney failure 21
For stroke prevention in atrial fibrillation, dialysis patients have increased bleeding risk and require careful monitoring with any anticoagulant, as suggested by the K/DOQI guidelines 22

Monitoring and Management

The American Society of Anesthesiologists recommends that for UFH during dialysis, activated partial thromboplastin time (aPTT) monitoring may be unreliable in inflammatory states; anti-Xa assay is preferred with target 0.5-0.7 IU/mL for therapeutic dosing 23
The American College of Cardiology suggests monitoring platelet count once or twice weekly if standard-dose UFH is used to detect heparin-induced thrombocytopenia (HIT) 23

Anticoagulation Strategies for Hemodialysis When Heparin Is Contraindicated

Acute Heparin‑Induced Thrombocytopenia (HIT) – Systemic Anticoagulation Required

Argatroban is recommended as the first‑line systemic anticoagulant for patients with acute HIT undergoing hemodialysis; standard therapeutic dosing does not need adjustment for renal impairment 24.
Danaparoid and bivalirudin are acceptable alternative agents when argatroban is unavailable, although they have additional limitations 24.
Danaparoid dosing protocol: an initial bolus (≈3,750 U, reduced to ≈2,500 U for patients with lower body weight) before the first two dialysis sessions, followed by maintenance doses (≈3,000 U, reduced to ≈2,000 U for lower‑weight patients) for subsequent sessions (Evidence level not specified) 24.
Fondaparinux and rivaroxaban should be avoided in acute HIT requiring dialysis because their anticoagulant effect depends on renal clearance 24.

Subacute or Remote HIT – Circuit‑Only Anticoagulation

Regional citrate anticoagulation is preferred over heparin or other non‑heparin systemic agents for patients with subacute or remote HIT who need anticoagulation only within the extracorporeal circuit 24.

General Guidance on Anticoagulant Selection

Do not use regional citrate for acute HIT that requires systemic anticoagulation 24.
When citrate is contraindicated in acute HIT, argatroban should be used first; if unavailable, danaparoid or bivalirudin may be considered 24.
For patients with subacute or remote HIT, regional citrate remains the preferred strategy 24.

All statements are based on the evidence presented in Blood Advances (2018) and the specific strength of evidence was not detailed in the source.